Compare Adaptive Biotechnologies Corp (ADPT) vs Aegon Ltd. (AEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Aegon Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Aegon Ltd. trades at $9.45 (market cap $14.01B). The key difference: Aegon Ltd. is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Aegon Ltd. pays a 4.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AEG | |
|---|---|---|
Market Cap | $4.04B | $14.01B |
Sector | Health | Financials |
52-Week High | $25.45 | $9.53 |
52-Week Low | $12.30 | $6.79 |
Enterprise Value | $4.10B | $15.16B |
Dividend Yield | — | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AEG trades at $9.45, down 0.84% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company maintains a P/E of 13.54 and P/S of 0.57, indicating potential undervaluation, while a strategic shift to U.S. focus and a $0.25 dividend highlight corporate stability.
The outlook is cautiously optimistic, supported by deleveraging trends and revenue growth projections to $26.9B in 2025. Risks include volatile cash flows and competitive pressures, but analyst consensus leans hold with 50% rating, suggesting steady performance amid transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →
